Byetta - First-in-Class Incretin Mimetic for Type 2 Diabetes

Developed by Amylin Pharmaceuticals, Inc, Byetta (exenatide) is a synthetic exendin-4 agent indicated for the treatment of type 2 diabetes in patients not on insulin and not achieving target levels with diet and standard oral medications. In 2002, Amylin signed a worldwide agreement with Eli Lilly to collaborate on the development and commercialisation of exenatide for type 2 diabetes.

Following successful completion of three large-scale phase III trials, Amylin and Lilly submitted a US NDA for exenatide in July 2004. In late April 2005, the drug received FDA approval for use as an adjunctive therapy to improve gluycaemic control in patients with type 2 diabetes who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea but have not achieved adequate glycaemic control. Now available in the US, exenatide is marketed under the brand name Byetta.

BYETTA - A NEXT-GENERATION DIABETES THERAPY

Exenatide is the first in a new class of compounds which possess similar activity to the naturally occurring hormone GLP-1 (glucagon-like peptide-1). Released from cells in the gut in response to food, GLP-1 binds to receptors on beta cells of the pancreas, thereby stimulating the release of insulin.

Exenatide mirrors the effects of GLP-1, which include glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, reduction of appetite and delay of food absorption. Since stimulation of insulin secretion occurs only in the presence of elevated blood-glucose concentrations and not during periods of normal or low blood-glucose concentrations, the risk of hypoglycaemia should be greatly reduced with Exenatide.

Exenatide may enable type 2 diabetics to control their blood-glucose levels while reducing or eliminating the risk of hypoglycaemia and weight gain, which would represent a significant therapeutic gain.

TYPE 2 DIABETES REPRESENTS A HUGE MARKET TO TAP

The World Health Organisation estimates that globally over150 million people have diabetes. Type 2 diabetes accounts for around 90% of all cases. Worldwide, the costs associated with treating diabetes and its complications are estimated to exceed $200 billion a year. By 2025 the prevalence of diabetes is predicted to double, driven by adverse lifestyle changes which have seen an explosion in the incidence of obesity, a risk factor for type 2 diabetes. Worldwide diabetes is a huge and growing problem and for which new treatments are needed.

CLINICAL TRIALS POINT TO POTENT BLOOD GLUCOSE-LOWERING EFFECTS

The anti-diabetic, glucose lowering effects of exenatide have been demonstrated in a series of phase II trials. Overall these have shown that exenatide:

• Stimulates secretion of insulin only in the presence of elevated blood glucose concentrations
• Lowers post-meal glucagon concentrations
• Slows gastric emptying thereby modulating absorption of glucose into the bloodstream
• Increases sensation of fullness and satiety
• Suppresses post-meal elevations in serum triglyceride concentrations
• Lowers blood glucose concentration with concomitant reductions in levels of HbA1c

In a phase II trial in over 100 subjects with poorly controlled type 2 diabetes, the addition of exenatide to ongoing oral medication produced a statistically significant reduction in HbA1c levels compared with the average reductions achieved with standard oral medications and placebo alone.

Because patients with type 2 diabetes often need to take anti-diabetic medications long term, phase III clinical trials were designed to examine the long-term impact of exenatide on HbA1c levels. Involving around 1,600 patients, the trials assessed the effects of adding exenatide to metformin, sulphonylureas and combinations of the two in patients poorly controlled on these standard agents. In each of the three phase III trials patients continued to use their existing oral anti-diabetic medication. Results showed that in all three pivotal studies the primary glucose control endpoint was met. Across the three studies the average reduction in HbA1c was 1% for patients on the highest 10mg twice-daily dose, while around 40% of patients on this dose achieved HbA1c measurements of 7% or less. Patients on 10mg exenatide twice daily also showed statistically significant reductions in body weight. Long-term, open-label extensions of the trials showed these benefits were maintained for a year. Data from the phase III trials was used to file for regulatory approval.

Exenatide appeared well-tolerated by patients enrolled in the clinical trial programme, with nausea the most common adverse effect. Studies suggest this can be reduced if dosage of Exenatide is increased gradually.

MARKETING COMMENTARY

Eli Lilly is already a major force in the diabetes market and the agreement reached with Amylin Pharmaceuticals for Byetta (exenatide) will strengthen its diabetes franchise. The target population for this new drug will be type 2 diabetic patients poorly controlled with diet plus metformin and/or sulfonylureas. At present these patients usually receive additional oral medications, to which insulin is sometimes added, or insulin therapy alone. Side effects, such as weight gain, are common.

Byetta (exenatide) is administered as a fixed-dose injection using a pen/cartridge delivery system. Longer-term, the aim is to have a long-acting, sustained release injection that can be given once a month. A long-acting release formulation (Exenatide LAR) is in development.

Click here for printable version